Refining indications for the use of mitomycin C using a randomized controlled trial with an animal model

被引:14
作者
Shvidler, Joseph [1 ]
Bothwell, Nici E. [1 ]
Cable, Benjamin [1 ]
机构
[1] Tripler Army Med Ctr, Otolaryngol Dept 3C, Honolulu, HI 96859 USA
关键词
D O I
10.1016/j.otohns.2006.10.037
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
OBJECTIVES: To evaluate the effect of mitomycin on the repair of acquired subglottic stenosis and to define the optimal concentration of mitomycin that would minimize restenosis after repair. STUDY DESIGN AND SETTING: A randomized prospective model was used in which 20 ferrets (Mustela putorius furo) underwent simulated intubation injury that was then treated with CO2 laser lysis. RESULTS: Comparison of cross-sectional airway areas, after stenosis repair, showed no significant differences between control and mitomycin treatment groups. Comparison of histologic scores for both inflammation and mucosalization yielded no difference between control and treatment animals. CONCLUSIONS: Mitomycin C appeared to have no benefit when placed after repair of an acquired stenosis. SIGNIFICANCE: This study closely models the injury experienced by children with acquired subglottic stenosis. These data provide clear evidence that mitomycin is limited in its effect on established wounds and help further define its role as an adjuvant for surgery in the aerodigestive tract. (C) 2007 American Academy of Otolaryngology-Head and Neck Surgery. Foundation. All rights reserved.
引用
收藏
页码:653 / 657
页数:5
相关论文
共 22 条
[1]   Differential activation of p53 by the various adducts of mitomycin C [J].
Abbas, T ;
Olivier, M ;
Lopez, J ;
Houser, S ;
Xiao, G ;
Kumar, GS ;
Tomasz, M ;
Bargonetti, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (43) :40513-40519
[2]  
Anduze AL, 2001, OPHTHALMIC SURG LAS, V32, P341
[3]   Mitomycin C for the treatment of pharyngoesophageal stricture after total laryngopharyngectomy and microvascular free tissue reconstruction [J].
Annino, DJ ;
Goguen, LA .
LARYNGOSCOPE, 2003, 113 (09) :1499-1502
[4]  
CABLE BB, 2002, OPER TECH OTOLARYNGO, V13, P57
[5]   PREFERENTIAL EFFECTS OF THE CHEMOTHERAPEUTIC DNA CROSS-LINKING AGENT MITOMYCIN-C ON INDUCIBLE GENE-EXPRESSION IN-VIVO [J].
CARON, RM ;
HAMILTON, JW .
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 1995, 25 (01) :4-11
[6]   Mitomycin C for the prevention of adhesion formation after endoscopic sinus surgery: A randomized, controlled study [J].
Chung, JH ;
Cosenza, MJ ;
Rahbar, R ;
Metson, RB .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2002, 126 (05) :468-474
[7]  
Cummings J, 1998, BIOCHEM PHARMACOL, V56, P405
[8]   Can topical mitomycin prevent laryngotracheal stenosis? [J].
Eliashar, R ;
Eliachar, I ;
Esclamado, R ;
Gramlich, T ;
Strome, M .
LARYNGOSCOPE, 1999, 109 (10) :1594-1600
[9]   Mitomycin does not prevent laryngotracheal repeat stenosis after endoscopic dilation surgery: An animal study [J].
Eliashar, R ;
Gross, M ;
Maly, B ;
Sichel, JY .
LARYNGOSCOPE, 2004, 114 (04) :743-746
[10]   RNA interference targeting transforming growth factor-β enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo [J].
Friese, MA ;
Wischhusen, J ;
Wick, W ;
Weiler, M ;
Eisele, G ;
Steinle, A ;
Weller, M .
CANCER RESEARCH, 2004, 64 (20) :7596-7603